SkinBioTherapeutics

SkinBioTherapeutics is a publicly-traded biotech focused on harnessing the skin microbiome to develop innovative health solutions. Founded in 2015, its core SkinBiotix® platform has led to the launch of the AxisBiotix-Ps™ supplement for psoriasis and a strategic expansion via acquisitions of Dermatonics and Bio-Tech Solutions. The company pursues a dual-path strategy: generating commercial revenue from consumer and OTC products to fund longer-term R&D ambitions across cosmetic, supplement, medical device, hygiene, and pharmaceutical sectors.

The SkinBiotix® platform is a live biotherapeutic technology based on beneficial bacteria and their metabolites, designed to modulate the skin microbiome and support skin barrier function for applications across cosmetics, supplements, and therapeutics.

SkinBioTherapeutics faces competition from nutraceutical companies in supplements, large chemical firms in cosmetic actives, and other microbiome-focused biotechs in therapeutics. Its differentiation lies in its proprietary platform, vertical integration, and early commercial revenue.